Demographics of unrelated donor umbilical cord blood versus bone marrow–methotrexate recipients and umbilical cord blood versus bone marrow–T-cell depletion recipients
| . | UCB . | BM-MTX . | P . | UCB . | BM-TCD . | P . |
|---|---|---|---|---|---|---|
| N | 26 | 26 | 31 | 31 | ||
| Age (y)* | NS | NS | ||||
| Median (range) | 4.5 (0.2-17.9) | 4.7 (0.6-17.7) | 5.8 (0.2-17.9) | 6.8 (0.5-1.7) | ||
| Weight (kg) | NS | NS | ||||
| Median (range) | 19.6 (5-78) | 19.7 (5.9-80) | 20.2 (5-91) | 21.0 (5.7-91) | ||
| Transplant year | < .05 | NS | ||||
| 1991-1993 | 0 (0%) | 5 (19%) | 0 (0%) | 1 (3%) | ||
| 1994-1999 | 26 (100%) | 21 (81%) | 31 (100%) | 30 (97%) | ||
| HLA disparity | ||||||
| 3/6 | 1 (4%) | 0 | 0 | 0 | ||
| 4/6 | 8 (31%) | 0 | 5 (16%) | 0 | ||
| 5/6 | 12 (46%) | 0 | 22 (71%) | 0 | ||
| 6/6 | 5 (19%) | 26 (100%) | 4 (13%) | 31 (100%) | ||
| Diagnosis* | NS | NS | ||||
| ALL | 10 (38%) | 10 (38%) | 8 (26%) | 8 (26%) | ||
| AML | 5 (19%) | 5 (19%) | 3 (10%) | 3 (10%) | ||
| MDS | 1 (4%) | 1 (4%) | 1 (3%) | 1 (3%) | ||
| CML | 1 (4%) | 1 (4%) | 0% | 0% | ||
| FA/SAA | 3 (12%) | 3 (12%) | 3 (10%) | 3 (10%) | ||
| Immunodeficiency | 3 (12%) | 3 (12%) | 0% | 0% | ||
| Storage disease | 3 (12%) | 3 (12%) | 16 (52%) | 16 (52%) | ||
| Risk* | NS | NS | ||||
| High | 15 (58%) | 15 (58%) | 24 (77%) | 24 (77%) | ||
| Standard | 11 (42%) | 11 (42%) | 7 (23%) | 7 (23%) | ||
| Cell dose × 108/kg | < .05 | NS | ||||
| Median (range) | 0.3 (0.1-2.8) | 2.0 (1.9-4.0) | 0.3 (0.1-2.8) | 0.5 (0.2-2) |
| . | UCB . | BM-MTX . | P . | UCB . | BM-TCD . | P . |
|---|---|---|---|---|---|---|
| N | 26 | 26 | 31 | 31 | ||
| Age (y)* | NS | NS | ||||
| Median (range) | 4.5 (0.2-17.9) | 4.7 (0.6-17.7) | 5.8 (0.2-17.9) | 6.8 (0.5-1.7) | ||
| Weight (kg) | NS | NS | ||||
| Median (range) | 19.6 (5-78) | 19.7 (5.9-80) | 20.2 (5-91) | 21.0 (5.7-91) | ||
| Transplant year | < .05 | NS | ||||
| 1991-1993 | 0 (0%) | 5 (19%) | 0 (0%) | 1 (3%) | ||
| 1994-1999 | 26 (100%) | 21 (81%) | 31 (100%) | 30 (97%) | ||
| HLA disparity | ||||||
| 3/6 | 1 (4%) | 0 | 0 | 0 | ||
| 4/6 | 8 (31%) | 0 | 5 (16%) | 0 | ||
| 5/6 | 12 (46%) | 0 | 22 (71%) | 0 | ||
| 6/6 | 5 (19%) | 26 (100%) | 4 (13%) | 31 (100%) | ||
| Diagnosis* | NS | NS | ||||
| ALL | 10 (38%) | 10 (38%) | 8 (26%) | 8 (26%) | ||
| AML | 5 (19%) | 5 (19%) | 3 (10%) | 3 (10%) | ||
| MDS | 1 (4%) | 1 (4%) | 1 (3%) | 1 (3%) | ||
| CML | 1 (4%) | 1 (4%) | 0% | 0% | ||
| FA/SAA | 3 (12%) | 3 (12%) | 3 (10%) | 3 (10%) | ||
| Immunodeficiency | 3 (12%) | 3 (12%) | 0% | 0% | ||
| Storage disease | 3 (12%) | 3 (12%) | 16 (52%) | 16 (52%) | ||
| Risk* | NS | NS | ||||
| High | 15 (58%) | 15 (58%) | 24 (77%) | 24 (77%) | ||
| Standard | 11 (42%) | 11 (42%) | 7 (23%) | 7 (23%) | ||
| Cell dose × 108/kg | < .05 | NS | ||||
| Median (range) | 0.3 (0.1-2.8) | 2.0 (1.9-4.0) | 0.3 (0.1-2.8) | 0.5 (0.2-2) |
UCB indicates umbilical cord blood; BM-MTX, bone marrow–methotrexate; BM-TCD, BM–T-cell depletion; NS, not significant; HLA, human leukocyte antigen; ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; MDS, myelodysplasia; CML, chronic myelogenous leukemia; FA, Fanconi anemia; SAA, severe aplastic anemia.
Indicates matching criteria.